Update (June 12, 2026): Bedinvetmab Global AE Data — 18 Million Doses, What the Numbers Show

TL;DR

Analysis of the Zoetis global pharmacovigilance database across 18.1 million doses of bedinvetmab found that all reported adverse events fell in the rare or very rare category; ataxia is rare but increased in 2024, potentially influenced by notoriety bias, and no cases met criteria for human-type rapidly progressive osteoarthritis.

What just dropped

• Monteiro BP et al. Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela). Front Vet Sci. 2025;12:1558222. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1558222/full — prospective pharmacovigilance data from the Zoetis Global Pharmacovigilance Database, launch (1 February 2021) through 30 June 2024. 18,102,535 doses distributed; 17,162 adverse events in 17,775 dogs; overall rate 9.48 events per 10,000 treated animals. The most frequently reported clinical signs were classified as rare (1 to 10 events per 10,000): lack of efficacy (1.70/10,000 — highest rate), polydipsia, ataxia, polyuria/pollakiuria, anorexia, lethargy, death, and emesis. All other reported clinical signs were very rare (<1/10,000). Musculoskeletal adverse events or reports including radiographs: 2,404 cases (1.33/10,000); none met criteria for rapidly progressive osteoarthritis as defined in humans. Median dog age with an adverse event was 12 years (IQR 10-13). Top five countries by adverse event frequency: Canada, US, UK, Australia, Germany.
• Farrell M et al. Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1581490/full — independent specialist disproportionality analysis of the EudraVigilance database (not the Zoetis database) reporting approximately 9-fold higher musculoskeletal adverse event rates for Librela vs. comparator OA drugs, and strong expert suspicion of causal association with accelerated joint destruction in a case series.

Context

The Monteiro et al. paper describes the data from the manufacturer's own global database, covering a substantially larger exposure period than any single regulatory source. The key finding is that the absolute frequency of all reported adverse events — including musculoskeletal and neurological signs — remains rare or very rare on a per-dose basis.

Ataxia reporting increased notably from June to October 2024 following the FDA's safety letter and media coverage, consistent with notoriety bias (increased spontaneous reporting after a safety alert rather than a true increase in incidence). Product labeling in multiple countries has been updated to reflect the potential causal association with ataxia and with polyuria/polydipsia/urinary incontinence.

The Farrell analysis (Article 3 in this series) used the EudraVigilance database with acknowledged completeness gaps for comparator drugs; the Monteiro paper uses the Zoetis proprietary database where completeness is better established. Both papers are essential context for clinical decision-making.

What this changes in Bedinvetmab (Librela) Adverse Events in Dogs (https://www.thevoyage.ai/forvets/knowledge/bedinvetmab-librela-adverse-events-dogs)

The existing evergreen summarizes AE signals based on earlier data. This 2025 global pharmacovigilance paper provides the most comprehensive denominator data available: 18 million doses with per-10,000 dose frequencies for all major VeDDRA terms. Clinicians can now contextualize individual case reports against population-level background rates. The absence of cases meeting human RPOA criteria is important but does not exclude all forms of accelerated joint deterioration.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-12-bedinvetmab-global-pharmacovigilance-data

References

1. Monteiro BP et al. Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela). Front Vet Sci. 2025;12:1558222. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1558222/full
2. Farrell M et al. Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1581490/full

Changelog

• 2026-06-12: First published.

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile